Previo appuntamento via e-mail: edoardo.francini@unifi.it

CURRICULUM VITAE

Edoardo Francini, M.D., Ph.D.

Ufficio: Dpt. di Medicina Sperimentale e Clinica, Università di Firenze, Largo Brambilla 3, Firenze

Email: edoardo.francini@unifi.it

ISTRUZIONE E FORMAZIONE 

• Laurea Specialistica in Medicina e Chirurgia, 110/110 con Lode. Tesi: Trattamento del carcinoma prostatico ormono-resistente: studio randomizzato di fase II, docetaxel ed epirubicina vs docetaxel e prednisone. Università degli Studi di Siena. 22 Luglio 2011.
• Abilitazione alla professione di medico chirurgo, 270/270. II sessione 2011 e iscrizione Albo Professionale Medici Chirurghi della Provincia di Siena n° 4651. 5 Marzo 2012.
• Internato laboratoristico con focus su valutazione stato mutazionale geni BRCA 1/2, includendo tecniche di estrazione e amplificazione del DNA, analisi PCR, sequenziamento e purificazione DNA ed analisi dati, presso il laboratorio della U.O.D. Oncologia Molecolare del Policlinico Umberto I, Roma. Ottobre 2012 – Giugno 2013.
• Research Fellowship in Oncologia Medica presso l’Ospedale Universitario Santa Maria alle Scotte,Siena. Luglio 2013 – Dicembre 2015.
• Research Fellowship in Oncologia Genitourinaria presso il Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute - Harvard Medical School, Boston (MA), USA. Gennaio 2016 – Giugno 2017.
• Research Fellowship in Oncologia Medica e Medicina presso la Harvard University, Boston (MA), USA. Marzo 2016 – Giugno 2017.
• Abilitazione Scientifica Nazionale Fascia II, settore concorsuale 06/D3 Malattie del Sangue, Oncologia e Reumatologia. 6 Aprile 2017 – 6 Aprile 2027.
• Certificato di Biostatistica Applicata – Harvard Catalyst Education Program, Harvard University, Boston (MA). 1 Luglio 2017.
• Specializzazione in Oncologia Medica con votazione 70/70 con Lode. Tesi: Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Sapienza Università di Roma. 13 Luglio 2017.
• PhD in Metodologia di Ricerca Sperimentale e Clinica in Oncologia con votazione Ottimo con Lode. Tesi: Circulating free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). Sapienza Università di Roma. 10 Febbraio 2020.
• Certificato di Investigator Site Personnel ICH Good Clinical Practice (GCP). 17 Febbraio 2020.

INCARICHI UNIVERSITARI

• Research Fellow in Oncologia Genitourinaria presso il Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute - Harvard Medical School, Boston (MA), USA. Gennaio 2016 – Giugno 2017.
• Research Fellow in Oncologia Medica e Medicina presso la Harvard University, Boston (MA), USA. Marzo 2016 – Giugno 2017.
• Professore a contratto presso la Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. 24 Maggio 2019 – Dicembre 2019.
• Professore a contratto presso la Scuola di Specializzazione in Ematologia, Università di Pisa. 21 Maggio 2019 – Dicembre 2019.
• Ricercatore a tempo determinato di tipo B di Oncologia Medica presso il Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze. 1 Giugno 2020 – in corso.
• Membro del Collegio della Scuola di Specializzazione in Otorinolaringoiatria, Università degli Studi di Firenze. Ottobre 2020 – Maggio 2022.
• Membro del Collegio della Scuola di Specializzazione in Medicina D’Emergenza-Urgenza, Università degli Studi di Firenze. Ottobre 2021 – in corso.
• Membro del Collegio della Scuola di Specializzazione in Medicina del Lavoro, Università degli Studi di Firenze. Ottobre 2021 – in corso.
• Membro del Collegio della Scuola di Specializzazione in Ematologia, Università degli Studi di Firenze. Ottobre 2021 – in corso.
• Membro del Collegio della Scuola di Specializzazione in Radiodiagnostica, Università degli Studi di Firenze. Ottobre 2021 – in corso.
• Membro del Collegio della Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. Dicembre 2021 – in corso.
• Delegato Aggiornamenti e Newsletter per il Collegio degli Oncologi Medici Universitari (COMU). Giugno 2022 – in corso.
• Visiting Professor a EOC Istituto Oncologico Svizzero Italiano (IOSI) e a Institute of Oncology Research (IOR) – Università della Svizzera Italiana, Bellinzona, Svizzera. 1 Ottobre 2022 – 31 marzo 2022.
• Membro del Collegio della Scuola di Specializzazione in Patologia clinica e Biochimica clinica, Università degli Studi di Firenze. Novembre 2022 – in corso.
• Membro del Collegio della Scuola di Specializzazione in Genetica Medica Non Medici, Università degli Studi di Firenze. Novembre 2022 – in corso.
• Professore Associato di Oncologia Medicapresso il Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze. 24 Gennaio 2023 (presa di servizio il 01/06/2023).

ATTIVITÀ CLINICO-ASSISTENZIALE

• Specialista Ambulatoriale di Oncologia Medica presso U.O.C. Oncologia Medica, Ospedale Misericordia, Grosseto. 1 Giugno 2018 – 31 Maggio 2020.
• Dirigente medico oncologo presso S.O.D.c. Oncologia Medica, A.O.U. Careggi, Firenze. 1 Giugno 2020 – 30 settembre 2022.
• Dirigente medico oncologo presso EOC Istituto Oncologico Svizzero Italiano (IOSI), Bellinzona, Svizzera. 1 Ottobre 2022 – 31 marzo 2022.
• Dirigente medico oncologo presso S.O.D.c. Oncologia Medica, A.O.U. Careggi, Firenze. 1 Aprile 2023 – in corso.

ESPERIENZA DI INSEGNAMENTO

• Docenza sostitutiva di Oncologia presso il Corso di Laurea in Infermieristica, Sapienza Università di Roma. Aprile 2013 – Maggio 2013.
• Tutoraggio clinico e di ricerca di studenti interni presso la U.O.C. di Oncologia Medica, Sapienza Università di Roma. Settembre 2012 – Giugno 2013.
• Tutoraggio clinico e di ricerca di studenti interni presso la U.O.C. di Oncologia Medica, Università degli Studi di Siena. Settembre 2013 – Dicembre 2015.
• Docenza sostitutiva di Oncologia presso il Corso di Laurea in Dietistica e Nutrizione, Università degli Studi di Siena. Novembre 2014 – Febbraio 2015.
• Presentazioni bimensili Journal Club del Lank Center for Genitourinary Oncology,Dana-Farber Cancer Institute - Harvard Medical School e del Brigham and Women’s Hospital, Boston (MA), USA. Settembre 2016 – Giugno 2017.
• Tutoraggio clinico e di ricerca di medici specializzandi e studenti interni presso la U.O.C. di Oncologia dell’Ospedale Misericordia di Grosseto – Da Ottobre 2018 a Maggio 2020.
• Docenza di Oncologia presso la Scuola di Specializzazione in Ematologia, Università di Pisa. 21 Maggio 2019 – 31 Dicembre 2019.
• Docenza di Oncologia presso la Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. 24 Maggio 2019 – 31 Dicembre 2019.
• Docenza di Oncologia presso la Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. 1 Giugno 2020 – in corso.
• Docenza di Oncologia presso il Corso di Laurea in Dietistica e Nutrizione, Università degli Studi di Firenze. 1 Giugno 2020 – in corso.
• Docenza di Oncologia presso il Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Firenze. 1 Giugno 2020 – in corso.
• Docenza di Oncologia presso la Scuola di Specializzazione in Otorinolaringoiatria, Università degli Studi di Firenze. 1 Giugno 2020 – in corso.
• Tutoraggio clinico e di ricerca di specializzandi presso la S.O.D.c Oncologia Medica, A.O.U. Careggi, Firenze. 1 Giugno 2020 – in corso.
• Docenza di Oncologia presso il Corso di Laurea in Scienze Infermieristiche, Università degli Studi di Firenze. 18 Ottobre 2021 – in corso.
• Relatore e correlatore di tesisti di Scienze Infermieristiche e Scienze dell’Alimentazione, Università degli Studi di Firenze. Dicembre 2021 – in corso.
• Docenza di Oncologia presso la Scuola di Scuola di Specializzazione in Patologia clinica e Biochimica clinica, Università degli Studi di Firenze. Novembre 2022 – in corso.
• Docenza di Oncologia presso la Scuola di Specializzazione in Genetica Medica Non Medici, Università degli Studi di Firenze. Novembre 2022 – in corso.

ATTIVITÀ PROFESSIONALE

Organizzazione, direzione e coordinamento o partecipazione di gruppi di ricerca nazionali e internazionali

• Partecipazione alle attività di ricerca del gruppo di ricerca Oncologia di Siena, U.O.C. Oncologia medica, AOUS Santa Maria alle Scotte, Siena. Gennaio 2006 – Luglio 2021.
• Partecipazione alle attività di ricerca del Gruppo di ricerca Oncologia Sapienza, U.O.C. Oncologia medica, Policlinico Umberto I, Roma. Luglio 2012– Settembre 2015.
• Partecipazione alle attività di ricerca del Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute – Harvard Cancer Center, Boston (MA), USA. Gennaio 2016 – in corso.
• Partecipazione alle attività di ricerca del Blood Biopsy Team, Broad Institute of MIT and Harvard, Cambridge (MA), USA. Febbraio 2016 – in corso.
• Partecipazione alle attività di ricerca del Gastroinstestinal Oncology Tumor Group, Mayo Clinic, Rochester (MN), USA. Ottobre 2016 – in corso.
• Organizzazione, direzione e coordinamento del gruppo di ricerca composto dalle seguenti istituzioni nazionali ed internazionali: Dana-Farber Cancer Institute - Harvard Cancer Center, Boston (MA), USA; Tom Baker Cancer Center, Calgary (AB), Canada; Mayo Clinic, Phoenix (AZ), USA; Fred Hutchinson Cancer Research Center, Seattle (WA), USA; Università Hospital Fundacion Jimenez Diaz, Autonomous University of Madrid, Madrid, Spagna; Ospedale Misericordia, Grosseto; Sapienza Università di Roma, Roma; Ospedale degli Infermi, Biella; AOUS Santa Maria alle Scotte, Siena. Settembre 2017 – Luglio 2021.
• Partecipazione alle attività di ricerca del gruppo ACCENT (Adjuvant Colon Cancer End Points). Novembre 2019 – in corso.
• Organizzazione, direzione e coordinamento del gruppo di ricerca SPARTACUSS (prostate cancer Specific Population-directed Androgen Receptor Targeted agents in north America, Canada, european Union, Switzerland, South america) composto dalle seguenti istituzioni nazionali ed internazionali: Institut Gustave Roussy, Villejuif, Francia; Istituto Oncologico della Svizzera Italiana, Bellinzona, Svizzera; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brasile; Centro de Hematologia e Oncologia (Cehon), Grupo Oncologia D'Or, Brasile; Dana-Farber Cancer Institute - Harvard Cancer Center, Boston (MA), USA; Tom Baker Cancer Center, Calgary (AB), Canada; Istituto Tumori della Romagna IRCSS, Meldola; Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; Università Campus Bio-medico di Roma, Roma; Istituto Nazionale Tumori, Milano; Azienda Provinciale per i Servizi Sanitari, Trento, Italy; Policlinico Universitario Paolo Giaccone, Palermo; Policlinico San Martino, Genoa, Italy. Agosto 2021 – in corso.
• Partecipazione alle attività di ricerca del gruppo di ricerca oncologico del Policlinico Universitario Paolo Giaccone, Palermo. Gennaio 2022 – in corso.
• Partecipazione alle attività di ricerca del gruppo Alimonti del Institute of Oncology Research (IOR) – Università della Svizzera Italiana, Bellinzona, Svizzera. 1 Ottobre 2022 – in corso.

Organizzazione, direzione e coordinamento o partecipazione a progetti di ricerca nazionali e internazionali

• Co-investigator, progetto di ricerca “A prospective registry of patients with a confirmed diagnosis of adenocarcinoma of the prostate presenting with metastatic castrate-resistant prostate cancer”, Janssen-Cilag. Agosto 2013 – in corso.
• Co-investigator, studio clinico "Tolerability of Single-Agent Sorafenib in the Treatment of Elderly Patients With Hepatocellular Carcinoma (HCC)" in collaborazione con Gruppo di ricerca Oncologia della U.O.C. Oncologia medica del Policlinico Umberto I, Roma ed il Gruppo di ricerca Oncologia della U.O.C. Oncologia medica del AOUS Santa Maria alle Scotte, Siena. Settembre 2013 – Agosto 2014.
• Co-investigator, “MED-GX301-02 - A randomised, parallel-group, open-label Phase II trial of the immunological effects of three regimens of GX301 vaccination in castration-resistant prostate cancer patients who have achieved response to first-line chemotherapy”, Mediolanum Farmaceutici. Ottobre 2015 – in corso.
• Co-investigator, studio traslazionale “Circulating cell-free DNA (cfDNA) of biomarkers predictive of resistance or response to taxane therapy to taxane treatment in metastatic castration-resistant prostate cancer (mCRPC)” Sapienza Università di Roma, Dana-Farber Cancer Institute - Harvard Medical School e Broad Institute of MIT and Harvard, Boston (MA), USA. Febbraio 2016 – in corso.
• Co-investigator, progetto traslazionale congiunto Università degli Studi di Siena e Mayo Clinic, Rochester (MN), USA “Evaluation of prognostic markers in colon cancer patients”. Ottobre 2016 – in corso.
• Co-investigator, studio clinico “CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multicenter, prospective, two-arm, open label, non inferiority phase II study”, Consorzio Oncotech. Febbraio 2017 – in corso.
• Co-investigator, studio clinico "Clinical outcomes of first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer after androgen deprivation therapy (ADT) + docetaxel or ADT alone for metastatic hormone-sensitive prostate cancer" in collaborazione con le seguenti Instituzioni: Dana-Farber Cancer Institute - Harvard Cancer Center, Boston (MA), USA; Tom Baker Cancer Center, Calgary (AB), Canada Genitourinary (GU) Tumor Group del Tom Baker Cancer Center, Calgary (AB), Canada; St Vincent’s Hospital, Sydney, Australia. Febbraio 2017 – Settembre 2017.
• Co-investigator, studio clinico “A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment (SOPHIA)”, Parexel International. Agosto 2017 – in corso.

• Principal investigator, studio clinico “Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry”, in collaborazione con le seguenti Istituzioni: Dana-Farber Cancer Institute - Harvard Cancer Center, Boston (MA), USA; Tom Baker Cancer Center, Calgary (AB), Canada; Mayo Clinic, Phoenix (AZ), USA; Fred Hutchinson Cancer Research Center, Seattle (WA), USA; Università Hospital Fundacion Jimenez Diaz, Autonomous University of Madrid, Madrid, Spagna; Ospedale Misericordia, Grosseto; Sapienza Università di Roma, Roma; Ospedale degli Infermi, Biella; AOUS Santa Maria alle Scotte, Siena. Settembre 2017 – Luglio 2021.

• Co-investigator, “New predictive biOmaRkers of activity and Efficacy of immune check point inhibitors in advanced non-small cell Lung cArcinoma (NSCLC) (CORELAB)”. Dicembre 2019 – in corso.
• Co-investigator, “Bevacizumab plus Atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR Tyrosine Kinase Inhibitor (BACH-NET)”, Istituto Oncologico Veneto IRCCS. Gennaio 2020 – in corso.
• Sub-investigator, “A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer”. Marzo 2021 – in corso.
• Principal investigator, Meet-URO 26 “Optimizing treatment sequence for mCRPC in senior men aged ≥75 years and men with high volume of disease”, del gruppo di ricerca SPARTACUSS (prostate cancer Specific Population-directed Androgen Receptor Targeted agents in north America, Canada, european Union, Switzerland, South america) composto dalle seguenti Istituzioni: Institut Gustave Roussy, Villejuif, Francia; Istituto Oncologico della Svizzera Italiana, Bellinzona, Svizzera; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brasile; Centro de Hematologia e Oncologia (Cehon), Grupo Oncologia D'Or, Brasile; Dana-Farber Cancer Institute - Harvard Cancer Center, Boston (MA), USA; Tom Baker Cancer Center, Calgary (AB), Canada; Istituto Tumori della Romagna IRCSS, Meldola; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli; Università Campus Bio-medico di Roma, Roma; Istituto Nazionale Tumori, Milano; Azienda Provinciale per i Servizi Sanitari, Trento; Policlinico Universitario Paolo Giaccone, Palermo; Policlinico San Martino, Genova. Agosto 2021 – in corso.
• Co-investigator, studio clinico “REducing disruption of Public transport service and prostate cancer Risk by a Whole Body Vibration (WBV) rEcording System: The Single-institution, prospective, interventional (REPRESS) study” in collaborazione conPoliclinico Universitario Paolo Giaccone, Palermo. Gennaio 2022 – in corso.
• Co-investigator, studio clinico“An international dataset discovering cancer predisposition and outcome related to deleterious variant of Homologous Recombination repair genes (SHARING)”in collaborazione conPoliclinico Universitario Paolo Giaccone, Palermo. Febbraio 2022 – in corso.

Incarichi editoriali

• Lead Guest Editor, Special Issue “Optimal Sequencing and/or Combination of the New Drugs in mCRPC” su BioMed Research International, IF: 3.246. Marzo 2015 – Agosto 2015.
• Ad hoc Reviewer, Oncotarget, IF: 3.331. Dicembre 2015.
• Ad hoc Reviewer, Journal of Translational Medicine, IF: 8.440. Settembre 2016.
• Ad hoc Reviewer, European Urology Oncology, IF: 7.479. Aprile 2020 – in corso.
• Ad hoc Reviewer, Cancers, IF: 6.575. Settembre 2020 – in corso.
• Topic Editor, Cancers,IF: 6.575. Febbraio 2021 – in corso.
• Lead Guest Editor, Special Issue “Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers”, Cancers,IF: 6.575. Aprile 2021 – in corso.
• Ad hoc Reviewer, European Journal of Cancer,IF: 10.002. Giugno 2021.
• Editorial Board Member, Clinicals in Surgery, IF: 1.995. Luglio 2021 – in corso.
• Editorial Board Member, Oncology Insights. Luglio 2021 – in corso.
• Ad hoc Reviewer, Medicina, IF: 2.948. Luglio 2021.
• Ad hoc Reviewer,International Journal of cancer, IF: 7.316. Dicembre 2021 – in corso.
• Ad hoc Reviewer, Journal of Clinical Oncology, IF: 44.544. Giugno 2022 – in corso.
• Ad hoc Reviewer, Lancet of Oncology, IF: 54.433. Luglio 2022 – in corso.
• Ad hoc Reviewer, Journal of Cancer Research and Clinical Oncology, IF: 4.322. Novembre 2022 – in corso.
• Editorial Board Member, Frontiers in Oncology, IF: 5.738. Maggio 2023 – in corso.
• Guest Editor, Special Issue “Morphomolecular Characterization of Neoplastic and Pre-Neoplastic Lesions in Solid Malignancies”, Biomedicines,IF: 4.757. Giugno 2023 – in corso.
• Editorial Board Member, Global Translational Medicine. Ottobre 2023 – in corso.

Organizzazione di congressi

• Membro del Comitato Scientifico, congresso Focus sul Carcinoma della Mammella nella Paziente Anziana – Roma, 28 Novembre 2013.
• Scientific Coordinator, congresso Focus sul Carcinoma della Mammella nella Paziente Anziana – Roma, 8 Ottobre 2014.
• Scientific Coordinator, 1st Rome International Meeting on Geriatric Oncology (RIMOG) New Targets and New Drugs for a Tailored Therapy – Roma, 4-5 Dicembre 2014.
• Scientific Coordinator, 1st Rome International Meeting of Geriatric Oncology RIMOG Satellite Symposium – Siena, 15 Ottobre 2015.
• Scientific Coordinator, 2^nd RIMOG New and Emerging Therapeutic Options in Geriatric Oncology – Firenze, 30 Giugno - 1 Luglio 2016.
• Scientific Coordinator, Il Paziente Oncologico Anziano Gestione e Trattamento – Siena, 23 Novembre 2018.

• Scientific Coordinator, 3rd RIMOG State of the Art and Novelties in Geriatric Oncology – Siena, 20 Settembre 2019.

Partecipazione in comitati consultivi

• Membro di Advisory Board Italfarmaco, Nuove Prospettive nella Gestione da Nausea e Vomito da Chemioterapia. Firenze, 1 Dicembre 2015.
• Membro di Commissione Onco-geriatrica dedicata al Paziente anziano con malattie cronico degenerative in collaborazione con OMCEO Roma e GOGI – Onlus (gruppo italiano di oncologia geriatrica). Maggio 2021 – in corso.
• Membro di commissione AIOM news. Aprile 2022 – in corso.

Appartenenza a società scientifiche

• Revisore dei conti e membro di GOGI (Gruppo Italiano di Oncologia Geriatrica). Marzo 2014 – in corso.
• Membro di ASCO (American Society of Clinical Oncology). Giugno 2015 – in corso.
• Membro di ESMO (European Society for Medical Oncology). Maggio 2017 – in corso.
• Membro di AIMUT (Accademia Italiana Multidisciplinare per l’Urologia Territoriale). Settembre 2017 – in corso.

• Membro di Meet-URO (Italian Network for Research in Urologic Oncology). Novembre 2018 – in corso.
• Membro di ACCENT (Adjuvant Colon Cancer End Points). Novembre 2019 – in corso.
• Membro di COMU (Collegio degli Oncologi Medici Universitari). Giugno 2020 – in corso.
• Membro di AIOM (Associazione Italiana di Oncologia Medica). Maggio 2022 – in corso.
• Membro di EAU (European Association of Urology). Settembre 2023 – in corso.

GRANTS

• Contributo liberale Roche per progetto traslazionale “Circulating cell-free DNA (cfDNA) of biomarkers predictive of resistance or response to taxane treatment in metastatic castration-resistant prostate cancer (mCRPC)” in collaborazione con Dana-Farber Cancer Institute – Harvard Medical School e Broad Institute of MIT and Harvard, Boston (MA), USA. 27 Novembre 2018.
• GOGI sponsorship per progetto traslazionale “Circulating cell-free DNA (cfDNA) of biomarkers predictive of resistance or response to taxane treatment in metastatic castration-resistant prostate cancer (mCRPC)” in collaborazione con Dana-Farber Cancer Institute – Harvard Medical School e Broad Institute of MIT and Harvard, Boston (MA), USA. 26 Settembre 2018.

ATTIVITÀ SCIENTIFICA

Pubblicazioni peer-reviewed

1. Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença L, Oliveira TM, Patrikidou A, Vauchier C, Pereira Mestre R, Modesti M, Pignata S, Procopio G, Fornarini G, Ugo De Giorgi U, Russo A, Francini E. Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer. Ther Adv Med Oncol. 2023 March 3;15. doi:10.1177/17588359231156147. IF: 4.9
2. Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença Bueno L, Andrade LM, Patrikidou A, Pereira Mestre R, Modesti M, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E; on behalf of the SPARTACUSS Investigators. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023 Feb 3;21(1):75. doi: 10.1186/s12967-022-03861-2. IF: 7.4
3. Gristina V, Barraco N, La Mantia M, Castellana L, Insalaco L, Bono M, Perez A, Sardo D, Inguglia S, Iacono F, Cutaia S, Bazan Russo TD, Francini E, Incorvaia L, Badalamenti G, Russo A, Galvano A, Bazan V. Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. Cancers (Basel). 2022; 14(23):6013. https://doi.org/10.3390/cancers14236013. IF: 5.2
4. Galvano A, Castellana L, Gristina V, La Mantia M, Insalaco L, Barraco N, Perez A, Cutaia S, Calò V, Bazan Russo, TD, Francini E, Incorvaia L, Mirisola MG, Vieni S, Rolfo C, Bazan V, Russo A. The Diagnostic Accuracy of PIK3CA Mutations by circulating tumor DNA (ctDNA) in Breast Cancer: An Individual Patient Data Meta-analysis. Ther Adv Med Oncol. 2022 Sep 26;14:17588359221110162. IF: 4.9
5. Francini E, Fanelli GN, Pederzoli F, Spisak S, Minonne E, Raffo M, Pakula H, Scatena C, Naccarato AG, Loda M, Nuzzo PV. Circulating cell-free DNA in Renal Cell Carcinoma: the new era of precision medicine. Cancers (Basel). 2022 Sep 7;14(18):4359. IF: 5.2
6. Fanale D, Corsini LR, Brando C, Dimino A, Filorizzo C, Magrin L, Sciacchitano R, Fiorino A, Bazan Russo TD, Calò V, Iovanna JL, Francini E, Russo A, Bazan V. Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength. Front Oncol. 2022 Feb 9;12:827822. IF: 5.2
7. Francini E, Ou FS, Rhoades J, Wolfe EG, O'Connor EP, Ha G, Gydush G, Kelleher KM, Bhatt RS, Balk SP, Sweeney CJ, Adalsteinsson VA, Taplin ME, Choudhury AD. Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer.Cancers (Basel). 2021 Aug 12;13(16):4055. IF: 5.2
8. Francini E, Montagnani F, Nuzzo PV, Gonzalez-Velez M, Alimohamed NS, Rosellini P, Moreno-Candilejo I, Cigliola A, Rubio-Perez J, Crivelli F, Shaw GK, Zhang L, Petrioli R, Bengala C, Francini G, Garcia-Foncillas J, Sweeney CJ, Higano CS, Bryce AH, Harshman LC, Lee-Ying R, Heng DYC. Association of concomitant bone resorption inhibitors with overall survival among patients with metastatic castration-resistant prostate cancer and bone metastases receiving abiraterone acetate with prednisone as first-line therapy.JAMA Netw Open. 2021 Jul 1;4(7):e2116536. IF: 13.8
9. Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts R, Hubbard JM, Yoon HH, Francini G. The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study.Transl Oncol. 2021 Feb;14(2):100973. IF: 5.0
10. McGregor B, Zhang L, Gray KP, Shaw G, Evan C, Francini E, Sweeney C. Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):341-348. IF: 4.8
11. Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q. Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database. J Natl Cancer Inst. 2021 Apr 6;113(4):400-407. IF: 10.3
12. Francini E, Miano ST, Fiaschi AI, Francini G. Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2. Med Hypotheses. 2020 Nov; 144:110054. IF: 4.7
13. Miano ST, Francini E, Petrioli R, Francini G.A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient. Future Oncol. 2020Jan; 16(1s):33-38. IF: 3.3
14. Petrioli R, Mazzei MA, Giorgi S, Cesqui E, Gentili F, Francini G, Volterrani L, Francini E. Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study. Anticancer Drugs. 2020 Feb; 31(2):190-195. IF: 2.3
15. Petrioli R, Francini E, Cherri S, Marrelli D, Rovello F, Fiaschi AI, Miano ST, Savelli V, Calomino N, Farsi M, Vernillo R, Francini G. Feasibility of modified docetaxel, oxaliplatin, capecitabine (DOC) followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer. Anticancer Drugs. 2019 Mar;31(3):292-297. IF: 2.3
16. Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea AC, Cappabianca S, Bocchetti M, D’Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P. GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients. A critical review on a long lasting follow up. Journal: Frontiers in Oncology, section Cancer Immunity and Immunotherapy. Front Oncol. 2019 Nov; 9:1102. IF: 5.2
17. Petrioli R, Marrelli D, Roviello F, d'Ignazio A, Torre, Chirra M, Savelli V, Ambrosio MR, Francini G, Calomino N, Farsi M, Vernillo R, Francini E. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer. J Surg Oncol. 2019 Mar; 32:2-7. IF: 2.5
18. Petrioli R, Torre P, Pesola G, Paganini G, Paolelli L, Miano ST, Martellucci I, Francini G, Francini E. Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer. J Geriatr Oncol. 2019 May; 11(4):647-651. IF: 3.0
19. Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ. Impact of New Systemic Therapies on Overall Survival of Patients with Metastatic Castration Resistant Prostate Cancer in a Hospital-based Registry. Prostate Cancer Prostatic Dis. 2019 Sep; 22(3):420-427. IF: 4.8
20. Miracco C, Francini E, Torre P, Baldino G, Chirra M, Cinotti E, Francini G. Extramammary invasive Paget's disease and apocrine angiomatous hamartoma: an unusual association. Eur J Dermatol. 2018 Dec; 28(6):853-855. IF: 3.2
21. Choudhury AD, Werner L, Francini E, Wei XX, Ha G, Freeman SS, Rhoades J, Reed SC, Gydush G, Rotem D, Lo C, Taplin ME, Harshman LC, Zhang Z, O’Connor EP, Stover DG, Parsons HA, Getz G, Meyerson M, Love JC, Hahn WC, Adalsteinsson VA. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 Nov; 3(21):e122109. IF: 8.0
22. Petrioli R, Francini E, Cherri S, Torre P, Fiaschi AI, Miano ST, Marrelli D, Rovello F, Francini G. Capecitabine plus oxaliplatin and bevacizumab, followed by maintenance treatment with capecitabine and bevacizumab for patients aged > 75 years with metastatic colorectal cancer. Clin Colorectal Cancer. 2018Dec; 17(4):e663-e669. IF: 3.4
23. Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018 Sep; 78:889-95. IF: 2.8
24. Petrioli R, Chirra M, Messuti L, Fiaschi AI, Savelli V, Martellucci I, Francini E. Efficacy and safety of regorafenib with schedule 2/1 for patients ≥75 years with metastatic colorectal cancer (mCRC) after failure of two lines of chemotherapy. Clin Colorectal Cancer. 2018 Dec; 17(4):307-312. IF: 3.4
25. Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ. Clinical outcomes of first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer after androgen deprivation therapy + docetaxel or adt alone for metastatic hormone-sensitive prostate cancer. Clin Genitourin Cancer. 2018 Apr; 16(2):130-134. IF: 3.2
26. Moreira RB, Debiasi M, Francini E, Nuzzo PV, De Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide a meta-analysis of randomized controlled trials. Oncotarget. 2017 Aug; 8:84572-84578. IF: 5.168
27. Francini E,Taplin ME. Prostate cancer: developing novel approaches to castration-sensitive disease. Cancer. 2017 Jan; 123(1):29-42.IF: 6.2
28. Francini E,Sweeney CJ.Docetaxel activity in the era of life-prolonging hormonal therapies for metastatic castration-resistant prostate cancer. Eur Urol. 2016Sep; 70(3):410-2. IF: 23.4
29. Petrioli R, Roviello G, Zanotti L, Roviello F, Polom K, Bottini A, Marano L, Francini E, Marrelli D, Generali D. Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016 Jun;102:82-8. IF: 6.2
30. Petrioli R, Francini E, Roviello G. Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol. 2015 Oct; 6(5):99-103. IF: 2.8
31. Roviello G, Francini E,Perrella A, Laera L, Mazzei MA, Guerrini S, Petrioli R. An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer.Cancer Biol Ther. 2015; 16(12):1720-5. IF: 3.6
32. Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, Marrelli D, Roviello F, Bianco V, Francini E. Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer. Future Oncol. 2015 Sep; 11(18):2563-74 IF: 3.3
33. Petrioli R, Francini E, Roviello F, Marrelli D, Miano ST, Fiaschi AI, Laera L, Bellini MA, Roviello G. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥75years with impaired performance status. J Geriatr Oncol. 2015 Sep; 6(5):380-6IF: 3.0
34. Francini E, Fiaschi AI, Petrioli R, Bianco V, Laera L, Francini F, Roviello G. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.Anticancer Drugs. 2015 Sep; 26(8):910-1. IF: 2.3
35. Petrioli R, Francini E, Laera L, Fiaschi AI, Ponchietti R, Roviello G. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.Cancer Chemother Pharmacol. 2015 Sep; 76(3):439-45. Epub 2015 Jun 17. IF: 3.0
36. Petrioli R, Roviello G, Laera L, Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Martellucci I, Bianco V, Francini E. Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: a single-institution experience. Clin Lung Cancer. 2015 Nov; 16(6):e229-34. IF: 3.6
37. Francini E, Fiaschi AI, Petrioli R, Laera L, Bianco V, Ponchietti R, Roviello G.Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.Anticancer Drugs. 2015 Sep; 26(8):884-7. IF: 2.3
38. Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, Bianco V, Francini E. Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study. Anticancer Drugs. 2015 Sep; 26(8):878-83. IF: 2.3
39. Roviello G,Petrioli R,Laera L, Francini E. The third line of treatment for metastatic prostate cancer patients: Option or strategy? Crit Rev Oncol Hematol. 2015 Sep; 95(3):265-71. IF: 6.2
40. Petrioli R, Francini E, Fiaschi AI, Laera L, Miano ST, DE Rubertis G, Roviello G.Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.Anticancer Res. 2015 May; 35(5):3097-102. IF: 2.435
41. Petrioli R, Francini E, Fiaschi AI, Laera L, Roviello G.Targeted Therapies for Prostate Cancer.Cancer Invest. 2015 Aug; 33(7):276-85. IF: 2.4
42. Petrioli R, Roviello G, Fiaschi AI, Laera L, Bianco V, Ponchietti R, Barbanti G, Francini E. Low-dose Estramustine Phosphate and concomitant low dose Acetylsalicyclic Acid in heavily pretreated patients with advanced castrate-resistant prostate cancer. crit 2015 Oct; 13(5):441-6. IF: 3.2
43. Petrioli R, Roviello G, Fiaschi AI, Laera L, Roviello F, Marrelli D, Francini E. Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. Anticancer Drugs. 2015 Jul; 26(6):682-6. IF: 2.3
44. Petrioli R, Francini E, Fiaschi AI, Laera L, Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Bianco V, Roviello G.Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.Med Oncol. 2015 Apr; 32(4):587. IF: 3.4
45. Petrioli R, Francini E, Roviello F, Marrelli D, Fiaschi AI, Laera L, Rossi G, Bianco V, Brozzetti S, Roviello G. Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Cancer Chemother Pharmacol. 2015 May; 75(5):941-7. IF: 3.0
46. Roviello G, Francini E, Perrella A, Laera L, Mazzei MA, Guerrini S, Roviello F, Marrelli D, Petrioli R.Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. Cancer Biol Ther. 2015 Apr 3; 16(4):493-7. IF: 3.6
47. Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Barbanti G, Bianco V, Brozzetti S, Francini E. Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.Med Oncol. 2015 Mar; 32(3):485. IF: 3.4
48. Petrioli R, Roviello G, Fiaschi AI, Laera L, Marrelli D, Roviello F, Francini E.Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.Cancer Chemother Pharmacol. 2015 Apr; 75(4):683-90. IF: 3.0
49. Francini E, Petrioli R, Fiaschi AI, Laera L, Roviello G. Effects of abiraterone acetate on chronic kidney disease in 2 patients wth metastatic castration-resistant prostate cancer. Medicine (Baltimore). 2014 Dec; 93(27):e163. IF: 1.817
50. Francini E, Mazzaroppi S, Fiaschi AI, Petrioli R, Laera L, Roviello G, Pira T, Pellicelli AM, Bianco V. Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma.J Am Geriatr Soc. 2014 Nov; 62(11):2204-5. IF: 6.3
51. Francini E, Petrioli R, Rossi G, Laera L, Roviello G.  PSA response rate as a surrogate rate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castrate-resistant prostate cancer: an analysis of 22 trials. Tumour Biol. 2014 Nov; 35(11):10601-7.
52. Francini E, Bianco V. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC). Hepatology. 2014 Aug; 60(2):764-5. IF: 13.5
53. Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther. 2014 Oct; 14(10):1135-40. IF: 4.2
54. Francini E,Roviello G.How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.Tumour Biol. 2014 Aug; 35(8):7391-2.
55. Francini E,Fiaschi AI, Petrioli R, Francini F, Bianco V, Perrella A, Paganini G, Laera L, Roviello G. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer. Anticancer Drugs. 2014 Apr; 25(4):472-477. IF: 2.3
56. Rossi L, Tomao F, Russo GL, Papa A, Zoratto F, Marzano R, Basso E, Giordani E, Verrico M, Ricci F, Pasciuti G, Francini E, Tomao S.Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study.Ther Clin Risk Manag. 2013 Nov; 9:457-462. IF: 2.8
57. Roviello G, Petrioli R, Francini E. Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer. Int J Biol Markers. 2013 Apr; 28(3):326-328. IF: 2.0
58. Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab; Multidisciplinary Oncology Group On Gastrointestinal Tumors. Cancer Invest. 2012 Jan; 30(1):65-71. IF: 2.4
59. Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, Roviello G, Martellucci I, Chiriacò G, Miano ST, Marzocca G, Manganelli A, Ponchietti R, Savelli V, Petrioli R. Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. Prostate Cancer. 2011 Aug 21. IF: 4.2
60. Francini F, Pascucci A, Francini E, Miano ST, Bargagli G, Ruggiero G, Petrioli R. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. J Am Dent Assoc. 2011 May; 142(5):506-13. IF: 3.9
61. Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G, Barbanti G, Ponchietti R, Francini G. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. Br J Cancer. 2011 Feb 15; 104(4):613-9. IF: 8.8
62. Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. Int J Clin Oncol. 2011 Jun; 16(3):264 9; IF: 3.3
63. Licchetta A, Correale P, Migali C, Remondo C, Francini E, Pascucci A, Magliocca A, Guarnieri A, Savelli V, Piccolomini A, Carli AF, Francini G. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. J Chemother. 2010 Jun; 22(3):201-4. IF: 1.8
64. Petrioli R, Bargagli G, Lazzi S, Pascucci A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI, Lorenzi B, Francini G. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.; the Multidisciplinary Oncology Group in Gastrointestinal Tumors. Anticancer Drugs. 2010 Mar; 21(3):313-9. IF: 2.3
65. Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev. 2008 Dec; 34(8):710-8. IF: 11.8
66. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P, Francini G. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 trial). Clin Cancer Res. 2008 Jul 1; 14(13):4192-9. IF: 11.5
67. Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli S, Tanzini G, Battistelli S, Lorenzi M, Roviello F, Francini G. Multidisciplinary Oncology Group on Gastrointestinal Tumors. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anticancer Drugs. 2008 Jan; 19(1):91-6. IF: 2.3
68. Petrioli R, Paolelli L, Francini E, Marsili S, Pascucci A, Sciandivasci A, de Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. Anticancer Drugs. 2007 Aug; 18(7):817-20. IF: 2.3
69. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 2007 Oct; 100(4):775-9. IF: 4.5
70. Francini G, Paolelli L, Francini E, Pascucci A, Manganelli A, Salvestrini F, Petrioli R. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. Eur J Surg Oncol. 2008 Feb; 34(2):216-21. IF: 3.8
71. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M, Francini G. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008 Jan; 61(1):105-11. IF: 3.0
72. Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology.  2007 Jan; 69(1):142-6. IF: 3.3
73. Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, Roviello F, Nettuno R, Intrivici C, Tanzini G, Lorenzi M, Francini G. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.Oncology. 2006 Dec 15; 70(5):345-50. IF: 3.5
74. Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer. 2006 Jul 17;95(2):153-8. IF: 8.8

Pubblicazioni dal n. 1 al n. 74:    Impact Factor = 361.985

                                                       H-index (Scopus, 30 ottobre 2023) = 21

                                                              Citazioni (Scopus, 30 ottobre 2023) = 1269

Abstracts/posters, capitoli di libro, editoriali

• Francini E, Gray KP, Xie W, Kantoff PW, Valenca L, Bernard B, Albiges L, Shaw G, Harshman LC, Taplin ME, Sweeney CJ. Prior Therapy and Volume of Disease are Prognostic for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Hospital-based Database. Poster al 2017 Genitourinary Cancers Symposium – ASCO Meetings, Orlando (FL), USA.J Clin Oncol 35, 2017 (suppl 6S; abstr 221).
• Francini E, Gray KP, Evan C, Kaymakcalan MD, Shaw GK, Kantoff PW, Taplin ME, Sweeney CJ. Outcomes of Prechemotherapy (pCHT) Abiraterone (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Deprivation Therapy (ADT) + Docetaxel (D) or ADT Alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Hospital-based Registry. Abstract al 2017 ASCO Annual Meeting, Chicago (IL), USA. J Clin Oncol 35, 2017 (suppl e16515).
• Kantoff PW, Spratt DE, Francini E. Androgen Blockade and Salvage Radiation Therapy in Prostate Cancer: Cautious Optimism Amid Unanswered Questions. Editoriale per ASCO Post, 10 Giugno 2017.
• Francini E, Yip S, Ahmed NS, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ. Outcomes of Prechemotherapy (preCRx) Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after ADT + Docetaxel (D) or ADT Alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Multi-Institution Hospital-based Registry. Poster al ESMO 2017 Congress, Madrid (Spagna). Ann Oncol 28, 2017 (suppl 5; abstr 806).
• Francini E, Gray KP, Shaw G, Evan C, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ. Impact of New Systemic Therapies on Overall Survival (OS) of Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) in a Hospital-based Registry. Poster al 2018 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 36, 2018 (suppl 6S; abstr 203).
• Zhang L, Gray KP, Shaw G, Evan C, Francini E, Sweeney CJ. Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases. Poster al 2018 ASCO Annual Meeting, Chicago (IL), USA. J Clin Oncol 36, 2018 (suppl; abstr 5049).
• Boccardo F, Francini E, Francini G, Zanardi E. Book chapter Neoplasie prostatiche. In: Manuale di oncologia medica. COMU Collegio degli Oncologi Medici Italiani, Aglietta M, editors. 2018; 246-64.
• Spini A, Roberto G, Ciccone V, Pascucci A, Rosellini P, Francini E, Donnini S, Gini R, Ziche M. Relevance of Gender In the Drug-utilization pattern of Non Small Cell Lung Cancer patients at University Hospital of Siena, Italy (UHS). Abstract al OSSD 2019, Washington (DC), USA.
• Frullanti E, Palmieri M, Baldassarri M, Fava F, Fabbiani A, Gelli E, Tita R, Torre P, Petrioli R, Hadijstilianou T, Galimberti D, Cinotti E, Mencarelli MA, Pinto AM, Francini E, Marsili S, Francini G, Renieri A. Specific clonal expansion at disease progression (PD) in solid cancers pinpointed by cell free DNA analysis. Abstract al 2019 ASCO Annual Meeting, Chicago (IL), USA. J Clin Oncol 37, 2019 (suppl; abstr e13144).
• Miano ST, Francini G, Petrioli R, Civitelli S, Francini E. Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT).Posteral 2019 ASCO Annual Meeting, Chicago (IL), USA.J Clin Oncol 37, 2019 (suppl; abstr 11052).
• Francini E, Montagnani F, Nuzzo P, Alimohamed NS, Moreno I, Rosellini P, Gonzalez-Velez M, Rubio-Perez J, Zhang L, Shaw GK, Crivelli F, Petrioli R, Bengala C, Francini G, Garcia-Foncillas J, Bryce AH, Sweeney CJ, Harshman LC, Lee-Ying R, Heng DYC. Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry. Abstract al 2019 ASCO Annual Meeting, Chicago (IL), USA. J Clin Oncol 37, 2019 (suppl; abstr e16508).
• Spini A, Roberto G, Bellan C, Rosellini P, Pascucci A, Donnini S, Caldarella A, Barchielli A, Furiesi F, Leoncini L, Francini E, Bartolini C, Giorgi S, Zappa M, Ziche M, Gini R. Using Linked Administrative And Pathology Database To Describe Treatment Patterns Of Non-small-cell Lung Cancer Patients At The Azienda Ospedaliera Universitaria Senese. Abstract al 35^th ICPE, 24-28 agosto 2019, Philadelphia (PA), USA.
• Correale P, Staropoli N, Pastina P, Giannicola R, Botta C, Francini E, Ridolfi L, Mini E, Ciliberto D, Agostino RM, Strangio A Azzarello D Nardone V, Falzea A, Tassone P, Giordano A, Pirtoli L, Francini, G, Tagliaferri, PS. GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis. Abstract al ESMO 2019 Congress, Barcellona (Spagna). Annal Oncol 30, 2019 (suppl 5; abstr 1204P).
• Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts SR, Hubbard JM, Yoon HH, Francini G. CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ). Poster al 2020 Gastrointestinal Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 38, 2020 (suppl; abstr 167)
• Francini E, Montagnani F, Nuzzo P, Gonzalez-Velez M, Alimohamed NS, Cigliola A, Moreno I, Rubio-Perez J, Crivelli F, Shaw GK, Petrioli R, Bengala C, Francini G, Garcia-Foncillas J, Bryce AH, Sweeney CJ, Higano CS, Harshman LC, Lee-Ying R, Heng DYC. Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) vs. AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database. Poster al 2020 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 38, 2020 (suppl; abstr 30).
• Francini E, Ou FS, Rhoades J, Wolfe EG, O’Connor E, Ha G, Gydush G, Kelleher KM, Bhatt RP, Balk SP, Sweneey CJ, Adalsteinsson V, Taplin ME, Choudhury AD.Circulating free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). Poster al 2020 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 38, 2020 (suppl; abstr 174).
• Boccardo F, Bianco R, Francini E, Zanardi E. Book chapter Neoplasie prostatiche. In: Manuale di oncologia medica. II edizione. COMU Collegio degli Oncologi Medici Italiani, Aglietta M, editors. Torino: Edizioni Minerva Medica; 2021; 273-89.
• Yang DD, Francini E, Jett Crowdis J, Bin Riaz I, Rickles-Young M; Tsuji J, Cibulskis C, Whelpley B, Reardon B, Park J, Huang FW, Van Allen EM, Choudhury AD. Genomic analysis of circulating tumor DNA identifies recurrent molecular features with clinical significance in advanced prostate cancer. Abstract al American Society for Radiation Oncology (ASTRO) 64^th Annual Meeting, 23-26 Ottobre 2022.
• Lee-Ying R, Saieva C, Nuzzo PV, Malgeri A, Fotia G, Zanardi E, Rossetti S, Valença L, Patrikidou A, Modesti M, Martins Oliveira T, Pignata S, Fornarini G, Procopio G, Santini D, Sweeney CJ, Heng DY, De Giorgi U, Russo A, Francini E. Clinical outcomes of Abiraterone Acetate (AA) or Enzalutamide (E) as 1st line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: a SPARTACUSS – Meet-URO 26 study. Poster al 2023 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol41, no. 6_suppl (February 20, 2023) 107-107.
• Gennusa V, Saieva C, Lee-Ying R, Nuzzo PV, Spinelli G, Zanardi E, Fotia G, Rossetti G, Valença L, Patrikidou A, Andrade L, Pereira Mestre R, Fornarini G, Procopio G, Santini D, Sweeney CJ, Heng DY, De Giorgi U, Russo A, Francini E. Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as 2nd line therapy (Rx) after progression on alternative ARSi as 1st line Rx for the elderly ≥75 years old with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: a SPARTACUSS – Meet-URO 26 study. Poster al 2023 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 41, no. 6_suppl (February 20, 2023) 166-166.

PRESENTAZIONI ORALI, SEMINARI, RUOLI CONGRESSUALI

• Francini E. Terapia Ormonale di Salvataggio nel Carcinoma della Prostata. Presentazione orale al congresso “L'integrazione Terapeutica con i Farmaci Target in Oncologia”. Roma, 4-5 Ottobre 2013.
• Francini E. Emesi, Anemia, Neutropenia. Presentazione orale al congresso “Focus sul Carcinoma della Mammella nella Paziente Anziana”. Roma, 28 Novembre 2013.
• Francini E. Gestione del Dolore nella Paziente Anziana con Malattia Metastatica. Presentazione orale al congresso “Focus sul Carcinoma della Mammella nella Paziente Anziana”. Roma, 8 Ottobre 2014.
• Francini E. Tumori Cerebrali: Terapia Medica e Protocolli Integrati. Presentazione orale al congresso “Diagnosi e Trattamento delle Neoplasie in Età Geriatrica”. Roma, 20 Febbraio 2015.
• Francini E. Nuovi Sviluppi nel Management della CINV. Presentazione orale in hospital meeting in collaborazione con Italfarmaco S.p.A. Siena, 13 Maggio 2015.
• Francini E. Gestione dell’Emesi e della Neutropenia. Presentazione orale al congresso “Focus sul Carcinoma della Mammella nella Paziente Anziana”. Roma, 30 Ottobre 2015.
• Francini E. Evoluzione delle Linee di Trattamento del Cancro Prostatico Metastatico: Note per l’Urologo Territoriale. Presentazione orale al congresso “V Congresso Nazionale AIMUT”. Pisa, 15-16 Settembre 2017.
• Francini E. Nuovi Orizzonti nel Trattamento del Carcinoma Prostatico Castration Naive. Presentazione orale al congresso “Approccio Multidisciplinare al Paziente con Carcinoma della Prostata: Specialisti a Confronto”. Rieti, 29 Settembre 2017.
• Francini E. Carcinoma della Prostata: Quali Prospettive per l’Immunoterapia? Presentazione orale al congresso “Immuno-Oncologia: Le Nuove Possibilità Terapeutiche”. Bari, 27 Novembre 2017.
• Francini E. Trattamento del mHSPC ed Implicazioni Terapeutiche Successive. Presentazione orale al congresso “Il Paziente Oncologico Anziano Gestione e Trattamento”. Siena, 23 Novembre 2018.
• Francini E. Role of Chemotherapy in Prostate Cancer. Presentazione orale al congresso “First International congress of Bioimmunotherapy of cancer An International multidisciplinary meeting”. Reggio Calabria, 12-14 Aprile 2019.
• Francini E. Il Ruolo della Chemioterapia nel Carcinoma della Prostata. Seminario alla Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. Firenze, 24 Luglio 2019.
• Francini E. Il Paziente Oligometastatico: Il Ruolo dell’Ormonoterapia. Presentazione orale al congresso “Prostate Cancer Match Point”. Napoli, 11-12 Ottobre 2019.
• Francini E. Terapia medica nei tumori della prostata castrazione-resistenti M0. Presentazione orale al “Congresso Regionale AURO.it Toscana”. Grosseto, 30 Novembre 2019.
• Francini E. Definizione e trattamento del carcinoma della prostata resistente alla castrazione non metastatico (nmCRPC).Seminario alla Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. Firenze, 21 Maggio 2021.
• Francini E. Carcinoma della prostata sensibile alla castrazione metastatico (mCSPC): attuale stato dell’arte. Seminario alla Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. Firenze, 3 Settembre 2021.
• Francini E. Carcinoma della prostata sensibile alla castrazione metastatico (mCSPC): stato dell’arte ed aggiornamenti. Seminario alla Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. Firenze, 29 Luglio 2022.
• Francini E. Il ruolo dei PARP-inibitori nel trattamento della malattia prostatica. Presentazione orale al congresso “Novità Nel Trattamento Integrato Dei Tumori Del Tratto Genito-Urinario”. Firenze, 27 Ottobre 2022.
• Francini E. La terapia ormonale nella sequenza terapeutica: apalutamide, abiraterone acetato, darolutamide e enzalutamide. Presentazione orale al congresso “Approccio multidisciplinare al paziente anziano con carcinoma della prostata: specialisti a confronto”. Roma, 2 Dicembre 2022.
• Francini E. Treatment of metastatic castration-sensitive prostate cancer (mCSPC): the clinical outliers. Seminario al HM Sanchinarro University Hospital. Madrid, Spagna, 25 Gennaio 2023.
• Francini E. Panel Discussant al congresso “EAU UROonco23”. Goteborg, Svezia, 30 giugno – 2 luglio 2023.
• Francini E. Carcinoma della prostata sensibile alla castrazione metastatico (mCSPC): stato dell’arte e strategie di trattamento. Seminario alla Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. Firenze, 13 Ottobre 2023.
• Francini E. Moderatore al congresso “Novità nel trattamento integrato dei tumori del tratto genito-urinario”. Firenze, 26 Ottobre 2023.
• Francini E. Role of the PARP inhibitors in the treatment of mCRPC. Seminario alla Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Firenze. Firenze, 10 Novembre 2023.

CAPACITÀ E COMPETENZE PERSONALI

• Public speaking
• Conoscenza delle seguenti lingue: 

-        Italiano (madrelingua)

-        Inglese (eccellente)

-        Spagnolo (eccellente)

-        Portoghese (eccellente)

Il sottoscritto Dott. Edoardo Francini dichiara che tutto quanto sopra citato corrisponde a verità ai sensi delle norme in materia di dichiarazioni sostitutive di cui agli artt. 46 e 47 del D.P.R. 445/2000. Ai sensi della legge 675/96, autorizza al trattamento dei dati personali contenuti nel presente Curriculum Vitae.

                                                                                                                                                             Firenze, 30/10/2023         

• Translational precision oncology for prostate cancer
• Tumor microenvironment factors for prognostic and predictive use
• Clinical outliers predictive of resistance to treatment
• Cell-free DNA as biomarker of resistance to therapy

Edoardo Francini is an Associate Professor of Medical Oncology at the University of Florence, Italy,teaching at numerous graduate schools and residency programs. After graduating with honors in Medicine and Surgery, he trained at the Sapienza University of Rome, Italy, to specialize with honors in Medical Oncology. During his residency program, he carried on a Research Fellowship in Genitourinary Oncology at the Dana-Farber Cancer Institute - Harvard Medical School, Boston (MA), USA, where he was tutored by Prof. Christopher J. Sweeney and Prof. Mary-Ellen Taplin and a Research Fellowship in Medical Oncology at the University of Harvard, Boston (MA), USA. He earned with honors his PhD in Methodology of Clinical and Experimental Research in Oncology at the Sapienza University of Rome. As Assistant Professor at the University of Florence, Italy, he spent 6 months as Visiting Professor at the Oncology Institute of Southern Switzerland and at the Institute of Oncology Research, Bellinzona, Switzerland, where he worked on translational mechanisms responsible for prostate cancer progression. Hisscientific research has largely focused on the identification of prognostic and predictive biomarkers, both translational and clinical, and precision medicine for prostate cancer.

CURRICULUM VITAE

Edoardo Francini, M.D., Ph.D.

Office address:  Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, Florence 50134, Italy

Email:  edoardo.francini@unifi.it

EDUCATION

• Master's degree in Medicine and Surgery, with honors. Thesis:Treatment of advanced castrate-resistant prostate cancer: a randomized phase II study, docetaxel and epirubicin vs docetaxel and prednisone.University of Siena, Siena, Italy. July 22, 2011.
• Medical Licensure, II session of Academic year 2011. Registered with n° 4651 at Albo Professionale Medici Chirurghi della Provincia di Siena (Siena Medical Licensing Board). March 5, 2012.
• Internship with focus on evaluation of BRCA 1/2 mutational status, including techniques of DNA extraction and amplification, PCR analysis, DNA sequencing and purification, and data analysis, in the laboratory of the Department of Molecular Oncology, Policlinico Umberto I hospital, Rome, Italy. October 2012 – June 2013.
• Research Fellowship in the Department of Medical Oncology of the Santa Maria alle Scotte Hospital in Siena, Italy. July 2013 – December 2015.
• Research Fellowship in the Lank Center for Genitourinary Oncology of the Dana-Farber Cancer Institute - Harvard Medical School, Boston (MA), USA. January 2016 – June 2017.
• Research Fellowship in Medical Oncology at the Harvard University, Boston (MA), USA. March 2016 – June 2017.
• National Scientific Qualification (ASN) as Associate Professor of Hematology, Oncology, and Rheumatology. April 6, 2017 – April 6, 2027.
• Certificate in Applied Biostatistics – Harvard Catalyst Education Program, Harvard University, Boston (MA), USA. July 1, 2017.
• Medical Oncology specialty – final mark 70/70 Cum Laude. Thesis: Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Sapienza University of Rome, Rome, Italy. July 13, 2017.
• PhD in Methodology of Clinical and Experimental Research in Oncology – final mark Summa Cum Laude. Doctoral dissertation: Circulating free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). Sapienza University of Rome, Rome, Italy. February 10, 2020.
• Investigator ICH Good Clinical Practice (GCP) Training Certificate. February 17, 2020.

UNIVERSITY APPOINTMENTS

• Research Fellow in Medical Oncology at the Harvard University, Boston (MA), USA. March 2016 – June 2017.
• Research Fellow in the Lank Center for Genitourinary Oncology of the Dana-Farber Cancer Institute - Harvard Medical School, Boston (MA), USA. January 2016 – June 2017.

• Adjunct Professor at the Medical Oncology Residency Program, University of Florence, Florence, Italy. May 24, 2019 – December 31, 2019.
• Adjunct Professor at the Hematology Residency Program, University of Pisa, Pisa, Italy. May 21, 2019 – December 31, 2019.
• Visiting Professor at EOC Istituto Oncologico Svizzero Italiano (IOSI) and at Institute of Oncology Research (IOR) – Università della Svizzera Italiana, Bellinzona, Svizzera. October 1, 2022 – March 1, 2023.
• Member of the Board of the Clinical Pathology and Clinical Biochemistry Residency Program, University of Florence, Italy. November 1, 2022 – Present.
• Member of the Board of the Medical Genetics Residency Program, University of Florence, Italy. November 1, 2022 – Present.
• Associate Professor of Medical Oncology at the Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. January 24, 2023 (starting on June 1, 2023).

• Tenure Track Assistant Professor of Medical Oncology at the Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. June 1, 2020 – May 31, 2022.
• Member of the Board of the Otolaryngology Residency Program, University of Florence, Florence, Italy.  October 2020 – Present.
• Member of the Board of the Emergency Medicine Residency Program, University of Florence, Florence, Italy.  October 2021 – Present.
• Member of the Board of the Occupational Medicine Residency Program, University of Florence, Florence, Italy.  October 2021 – Present.
• Member of the Board of the Hematology Residency Program, University of Florence, Florence, Italy.  October 2021 – Present.
• Member of the Board of the Diagnostic Radiology Residency Program, University of Florence, Florence, Italy.  October 2021 – Present.
• Member of the Board of the Oncology Residency Program, University of Florence, Florence, Italy.  December 2021 – Present.
• Delegate to Updates and Newsletters for Collegio degli Oncologi Universitari (COMU). June 2022 – Present.

WORK EXPERIENCE

• Medical Oncologist – U.O.C. Medical Oncology, Misericordia Hospital, Grosseto, Italy. June 1, 2018 – May 31, 2020.
• Medical Oncologist – S.O.D.c Medical Oncology, Careggi Hospital, Firenze, Italy. June 1, 2020 – September 30, 2022.
• Medical Oncologist – EOC Istituto Oncologico Svizzero Italiano (IOSI), Bellinzona, Switzerland. October 1, 2022 – March 31, 2023.
• Medical Oncologist – S.O.D.c Medical Oncology, Careggi Hospital, Firenze, Italy. April 1, 2022 – Present.

TEACHING EXPERIENCE

• Substitute Lecturer of Oncology at the School of Nursing, Sapienza University of Rome, Rome, Italy. April 2013 – May 2013.
• Research and Clinical Supervisor of medical students at the Medical Oncology Unit outpatient service, Umberto I Hospital, Rome, Italy. September 2012 – June 2013. 
• Research and Clinical Supervisor of medical students and interns at the Medical Oncology Unit inpatient service, Siena Hospital, Siena,Italy. September 2013 – December 2015. 
• Substitute Lecturer of Oncology at the School of Nutrition and Dietetics, University of Siena, Siena, Italy. November 2014 – February 2015.
• Oral presentations at the Dana-Farber Cancer Institute - Harvard Medical School and Brigham and Women’s Hospital joint Journal Club, Boston (MA), USA. September 2016 – June 2017.
• Research and Clinical Supervisor of resident physicians and medical students and interns at the Medical Oncology Unit inpatient service, Misericordia Hospital, Grosseto, Italy. October 2018 – May 31, 2020.
• Lecturer of Oncology at the Hematology Residency Program, University of Pisa, Pisa, Italy. May 21, 2019 – December 31, 2019.
• Lecturer of Oncology at the Medical Oncology Residency Program, University of Florence, Florence, Italy. May 24, 2019 – December 31, 2019.

• Lecturer of Oncology at the Medical Oncology Residency Program, University of Florence, Florence, Italy. June 1, 2020 – Present.
• Lecturer of Oncology at the School of Nutrition and Dietetics, University of Florence, Florence, Italy. June 1, 2020 – Present.
• Lecturer of Oncology at the School of Medicine and Surgery, University of Florence, Florence, Italy. June 1, 2020 – Present.
• Lecturer of Oncology at the Otolaryngology Residency Program, University of Florence, Florence, Italy. June 1, 2020 – Present.

• Research and Clinical Supervisor of resident physicians at Careggi Hospital, Florence, Italy. June 1, 2020 – Present.
• Lecturer of Oncology at the School of Nursing, University of Florence, Florence, Italy. October 18, 2021 – Present.
• Supervisor and co-supervisor of Nursing School and Nutritional Science School graduating students. December 2021 – Present.
• Lecturer of Oncology at the Clinical Pathology and Clinical Biochemistry Residency Program, University of Florence, Florence, Italy. November 1, 2022 – Present.
• Lecturer of Oncology at the Medical Genetics Residency Program, University of Florence, Florence, Italy. November 1, 2022 – Present.

PROFESSIONAL ACTIVITY

Direction, coordination, or participation in national/international research projects

• Co-investigator, “A prospective registry of patients with a confirmed diagnosis of adenocarcinoma of the prostate presenting with metastatic castrate-resistant prostate cancer”, Janssen-Cilag. August 2013 – Present.
• Co-investigator, "Tolerability of Single-Agent Sorafenib in the Treatment of Elderly Patients With Hepatocellular Carcinoma (HCC)" in collaboration with the following institutions: Medical Oncology Unit of Policlinico Umberto I Hospital, Rome (Italy) and Medical Oncology Unit of Santa Maria alle Scotte Hospital, Sienna (Italy). September 2013 – August 2014.
• Co-investigator, “MED-GX301-02 - A randomised, parallel-group, open-label Phase II trial of the immunological effects of three regimens of GX301 vaccination in castration-resistant prostate cancer patients who have achieved response to first-line chemotherapy”, Mediolanum Farmaceutici. October 2015 – Present.
• Co-investigator, translational study “Circulating cell-free DNA (cfDNA) of biomarkers predictive of resistance or response to taxane therapy to taxane treatment in metastatic castration-resistant prostate cancer (mCRPC)”, in collaboration with the following institutions: Dana-Farber Cancer Institute - Harvard Medical School, Broad Institute of MIT and Harvard, Sapienza Università di Roma. February 2016 – Present.
• Co-investigator, translational research project “Evaluation of prognostic markers in colon cancer patients” in collaboration with the following institutions: Mayo Clinic of Rochester and Università degli Studi di Siena. October 2016 – Present.
• Co-investigator, “CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multicenter, prospective, two-arm, open label, non inferiority phase II study (CABACARE)”, Oncotech. February 2017 – Present.
• Co-investigator, “A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment (SOPHIA)”, Parexel International. August 28, 2017 – Present.
• Co-investigator, "Clinical outcomes of first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer after androgen deprivation therapy (ADT) + docetaxel or ADT alone for metastatic hormone-sensitive prostate cancer" in collaboration with the following institutions: Dana-Farber Cancer Institute - Harvard Cancer Center, Boston (MA), USA; Tom Baker Cancer Center, Calgary (AB), Canada Genitourinary (GU) Tumor Group del Tom Baker Cancer Center, Calgary (AB), Canada; St Vincent’s Hospital, Sydney, Australia. February 1, 2017 – September 1, 2017.

• Principal investigator, “Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry”, in collaboration with the following institutions: Dana-Farber Cancer Institute - Harvard Cancer Center, Boston (MA), USA; Tom Baker Cancer Center, Calgary (AB), Canada; Mayo Clinic, Phoenix (AZ), USA; Fred Hutchinson Cancer Research Center, Seattle (WA), USA; Università Hospital Fundacion Jimenez Diaz, Autonomous University of Madrid, Madrid, Spagna; Ospedale Misericordia, Grosseto; Sapienza Università di Roma, Roma; Ospedale degli Infermi, Biella; AOUS Santa Maria alle Scotte, Siena. September 21, 2017 – July 2021.

• Co-investigator, “New predictive biOmaRkers of activity and Efficacy of immune check point inhibitors in advanced non-small cell Lung cArcinoma (NSCLC) (CORELAB)”. December 2019 – Present.
• Co-investigator, “Bevacizumab plus Atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR Tyrosine Kinase Inhibitor (BACH-NET)”, Istituto Oncologico Veneto IRCCS. January 30, 2020 – Present.
• Sub-investigator, “A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer”. March 30, 2021 – Present.
• Principal investigator, Meet-URO 26 “Optimizing treatment sequence for mCRPC in senior men aged ≥75 years and men with high volume of disease”, led by the SPARTACUSS investigators (prostate cancer Specific Population-directed Androgen Receptor Targeted agents in north America, Canada, european Union, Switzerland, South america) including the following institutions:Institut Gustave Roussy, Villejuif, France; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brasil; Centro de Hematologia e Oncologia (Cehon), Grupo Oncologia D'Or, Brasil; Dana-Farber Cancer Institute - Harvard Cancer Center, Boston (MA), USA; Tom Baker Cancer Center, Calgary (AB), Canada; Istituto Tumori della Romagna IRCSS, Meldola, Italy; Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy; Università Campus Bio-medico di Roma, Rome, Italy; Istituto Nazionale Tumori, Milan, Italy; Azienda Provinciale per i Servizi Sanitari, Trento, Italy; Policlinico Universitario Paolo Giaccone, Palermo, Italy; Policlinico San Martino, Genoa, Italy. August 2021 – Present.
• Co-investigator, “REducing disruption of Public transport service and prostate cancer Risk by a Whole Body Vibration (WBV) rEcording System: The Single-institution, prospective, interventional (REPRESS) study” in collaborazione conPoliclinico Universitario Paolo Giaccone, Palermo, Italy. January 2022 – Present.
• Co-investigator,“An international dataset discovering cancer predisposition and outcome related to deleterious variant of Homologous Recombination repair genes (SHARING)”in collaboration withPoliclinico Universitario Paolo Giaccone, Palermo, Italy. February 2022 – Present.

Editorial appointments

• Lead Guest Editor, Special Issue “Optimal Sequencing and/or Combination of the New Drugs in mCRPC” on BioMed Research International,IF: 3.411, March 2015 – August 2015.
• Ad hoc Reviewer, Oncotarget, IF: 3.331. December 2015.
• Ad hoc Reviewer, Journal of Translational Medicine, IF: 8.440. September 2016.
• Ad hoc Reviewer, European Urology Oncology, IF: 7.479. April 2020 – Present.
• Ad hoc Reviewer, Cancers, IF: 6.575. September 2020 – Present.
• Topic Editor, Cancers, IF: 6.575. February 20, 2021 – Present.
• Lead Guest Editor, Special Issue “Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers”, Cancers, IF: 6.575. April 27, 2021 – Present.
• Ad hoc Reviewer, European Journal of Cancer, IF: 10.002. June 2021.
• Editorial Board Member, Clinicals in Surgery. July 2021 – Present.
• Editorial Board Member, Oncology Insights, IF: 1.995. July 2021 – Present.
• Ad hoc Reviewer, Medicina, IF: 2.948. July 2021.
• Ad hoc Reviewer,International Journal of cancer, IF: 7.316. December 2021 – Present.
• Ad hoc Reviewer, Journal of Clinical Oncology, IF: 44.544. June 2022 – Present.
• Ad hoc Reviewer, Lancet of Oncology, IF: 54.433. July 2022 – Present.
• Ad hoc Reviewer, Journal of Cancer Research and Clinical Oncology, IF: 4.322. November 2022 – Present.
• Editorial Board Member, Frontiers in Oncology, IF: 5.738. May 2023 – Present.
• Guest Editor, Special Issue “Morphomolecular Characterization of Neoplastic and Pre-Neoplastic Lesions in Solid Malignancies”, Biomedicines,IF: 4.757. June 2023 – Present.
• Editorial Board Member, Global Translational Medicine. October 2023 – Present.

Organization of meetings

• Member of the Scientific Committee, Focus sul Carcinoma della Mammella nella Paziente Anziana. Rome (Italy) – November 28, 2013.
• Scientific Coordinator, Focus sul Carcinoma della Mammella nella Paziente Anziana. Rome (Italy) – October 8, 2014.
• Scientific Coordinator, 1^st Rome International Meeting on Geriatric Oncology (RIMOG) New Targets and New Drugs for a Tailored Therapy. Rome (Italy) – December 4-5, 2014.
• Scientific Coordinator, 1^st RIMOG Satellite Symposium. Sienna (Italy) – October 15, 2015.
• Scientific Coordinator, 2^nd RIMOG New and Emerging Therapeutic Options in Geriatric Oncology. Florence (Italy), June 30 – July 1, 2016.
• Scientific Coordinator, 3^rd RIMOG State of the Art and Novelties in Geriatric Oncology. Siena (Italy) – September 20, 2018.
• Scientific Coordinator, Il Paziente Oncologico Anziano Gestione e Trattamento. Siena (Italy) – November 23, 2018.

Advisory panels and consultancies

• Member of advisory board Italfarmaco, Nuove Prospettive nella Gestione da Nausea e Vomito da Chemioterapia. Florence, December 1, 2015.
• Member of Oncogeriatric Committee on the elderly patient with chronic degenerative diseases in collaboration with OMCEO Roma and GOGI (Italian Group of Geriatric Oncology) nonprofit association. May 6, 2021 – Present.
• Member of AIOM News. April 2022 – Present.

Membership of scientific societies

• Board of GOGI (Italian Group of Geriatric Oncology) nonprofit association. April 2014 – Present.
• ASCO (American Society of Clinical Oncology). June 2015 – Present.
• ESMO (European Society for Medical Oncology). May 2017 – Present.
• AIMUT (Accademia Italiana Multidisciplinare per l’Urologia Territoriale). September 20, 2017 – Present.
• Meet-URO (Italian Network for Research in Urologic Oncology). November 2, 2018 – Present.
• ACCENT (Adjuvant Colon Cancer End Points). November 7, 2019 – Present.
• COMU (Collegio degli Oncologi Medici Universitari). June 1, 2020 – Present.
• AIOM (Associazione Italiana di Oncologia Medica). May 8, 2022 – Present.

• EAU (European Association of Urology). September 4, 2023 – Present.

GRANTS

• GOGI sponsorship for the project “Circulating cell-free DNA (cfDNA) of biomarkers predictive of resistance or response to taxane treatment in metastatic castration-resistant prostate cancer (mCRPC)” in collaboration with Dana-Farber Cancer Institute – Harvard Medical School and Broad Institute of MIT and Harvard, Boston (MA), USA. September 26, 2018.
• Roche liberal donation for the project “Circulating cell-free DNA (cfDNA) of biomarkers predictive of resistance or response to taxane treatment in metastatic castration-resistant prostate cancer (mCRPC)” in collaboration with Dana-Farber Cancer Institute – Harvard Medical School and Broad Institute of MIT and Harvard, Boston (MA), USA. November 27, 2018.

SCIENTIFIC ACTIVITY

Peer-reviewed publications

1. Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença L, Oliveira TM, Patrikidou A, Vauchier C, Pereira Mestre R, Modesti M, Pignata S, Procopio G, Fornarini G, Ugo De Giorgi U, Russo A, Francini E. Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer. Ther Adv Med Oncol. 2023 March 3;15. doi:10.1177/17588359231156147. IF: 4.9
2. Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença Bueno L, Andrade LM, Patrikidou A, Pereira Mestre R, Modesti M, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E; on behalf of the SPARTACUSS Investigators. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023 Feb 3;21(1):75. doi: 10.1186/s12967-022-03861-2. IF: 7.4
3. Gristina V, Barraco N, La Mantia M, Castellana L, Insalaco L, Bono M, Perez A, Sardo D, Inguglia S, Iacono F, Cutaia S, Bazan Russo TD, Francini E, Incorvaia L, Badalamenti G, Russo A, Galvano A, Bazan V. Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. Cancers (Basel). 2022; 14(23):6013. https://doi.org/10.3390/cancers14236013. IF: 5.2
4. Galvano A, Castellana L, Gristina V, La Mantia M, Insalaco L, Barraco N, Perez A, Cutaia S, Calò V, Bazan Russo, TD, Francini E, Incorvaia L, Mirisola MG, Vieni S, Rolfo C, Bazan V, Russo A. The Diagnostic Accuracy of PIK3CA Mutations by circulating tumor DNA (ctDNA) in Breast Cancer: An Individual Patient Data Meta-analysis. Ther Adv Med Oncol. 2022 Sep 26;14:17588359221110162. IF: 4.9
5. Francini E, Fanelli GN, Pederzoli F, Spisak S, Minonne E, Raffo M, Pakula H, Scatena C, Naccarato AG, Loda M, Nuzzo PV. Circulating cell-free DNA in Renal Cell Carcinoma: the new era of precision medicine. Cancers (Basel). 2022 Sep 7;14(18):4359. IF: 5.2
6. Fanale D, Corsini LR, Brando C, Dimino A, Filorizzo C, Magrin L, Sciacchitano R, Fiorino A, Bazan Russo TD, Calò V, Iovanna JL, Francini E, Russo A, Bazan V. Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength. Front Oncol. 2022 Feb 9;12:827822. IF: 5.2
7. Francini E, Ou FS, Rhoades J, Wolfe EG, O'Connor EP, Ha G, Gydush G, Kelleher KM, Bhatt RS, Balk SP, Sweeney CJ, Adalsteinsson VA, Taplin ME, Choudhury AD. Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021 Aug 12;13(16):4055. IF: 5.2
8. Francini E, Montagnani F, Nuzzo PV, Gonzalez-Velez M, Alimohamed NS, Rosellini P, Moreno-Candilejo I, Cigliola A, Rubio-Perez J, Crivelli F, Shaw GK, Zhang L, Petrioli R, Bengala C, Francini G, Garcia-Foncillas J, Sweeney CJ, Higano CS, Bryce AH, Harshman LC, Lee-Ying R, Heng DYC. Association of concomitant bone resorption inhibitors with overall survival among patients with metastatic castration-resistant prostate cancer and bone metastases receiving abiraterone acetate with prednisone as first-line therapy. JAMA Netw Open. 2021 Jul 1;4(7):e2116536. IF: 13.8
9. Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts R, Hubbard JM, Yoon HH, Francini G. The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. Transl Oncol. 2021 Feb;14(2):100973. IF: 5.0
10. McGregor B, Zhang L, Gray KP, Shaw G, Evan C, Francini E, Sweeney C. Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):341-348. IF: 4.8
11. Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q. Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database. J Natl Cancer Inst. 2021 Apr 6;113(4):400-407. IF: 10.3
12. Francini E, Miano ST, Fiaschi AI, Francini G. Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2. Med Hypotheses. 2020 Nov; 144:110054. IF: 4.7
13. Miano ST, Francini E, Petrioli R, Francini G.A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient. Future Oncol. 2020Jan; 16(1s):33-38. IF: 3.3
14. Petrioli R, Mazzei MA, Giorgi S, Cesqui E, Gentili F, Francini G, Volterrani L, Francini E. Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study. Anticancer Drugs. 2020 Feb; 31(2):190-195. IF: 2.3
15. Petrioli R, Francini E, Cherri S, Marrelli D, Rovello F, Fiaschi AI, Miano ST, Savelli V, Calomino N, Farsi M, Vernillo R, Francini G. Feasibility of modified docetaxel, oxaliplatin, capecitabine (DOC) followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer. Anticancer Drugs. 2019 Mar;31(3):292-297. IF: 2.3
16. Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea AC, Cappabianca S, Bocchetti M, D’Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P. GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients. A critical review on a long lasting follow up. Journal: Frontiers in Oncology, section Cancer Immunity and Immunotherapy. Front Oncol. 2019 Nov; 9:1102. IF: 5.2
17. Petrioli R, Marrelli D, Roviello F, d'Ignazio A, Torre, Chirra M, Savelli V, Ambrosio MR, Francini G, Calomino N, Farsi M, Vernillo R, Francini E. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer. J Surg Oncol. 2019 Mar; 32:2-7. IF: 2.5
18. Petrioli R, Torre P, Pesola G, Paganini G, Paolelli L, Miano ST, Martellucci I, Francini G, Francini E. Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer. J Geriatr Oncol. 2019 May; 11(4):647-651. IF: 3.0
19. Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ. Impact of New Systemic Therapies on Overall Survival of Patients with Metastatic Castration Resistant Prostate Cancer in a Hospital-based Registry. Prostate Cancer Prostatic Dis. 2019 Sep; 22(3):420-427. IF: 4.8
20. Miracco C, Francini E, Torre P, Baldino G, Chirra M, Cinotti E, Francini G. Extramammary invasive Paget's disease and apocrine angiomatous hamartoma: an unusual association. Eur J Dermatol. 2018 Dec; 28(6):853-855. IF: 3.2
21. Choudhury AD, Werner L, Francini E, Wei XX, Ha G, Freeman SS, Rhoades J, Reed SC, Gydush G, Rotem D, Lo C, Taplin ME, Harshman LC, Zhang Z, O’Connor EP, Stover DG, Parsons HA, Getz G, Meyerson M, Love JC, Hahn WC, Adalsteinsson VA. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 Nov; 3(21):e122109. IF: 8.0
22. Petrioli R, Francini E, Cherri S, Torre P, Fiaschi AI, Miano ST, Marrelli D, Rovello F, Francini G. Capecitabine plus oxaliplatin and bevacizumab, followed by maintenance treatment with capecitabine and bevacizumab for patients aged > 75 years with metastatic colorectal cancer. Clin Colorectal Cancer. 2018Dec; 17(4):e663-e669. IF: 3.4
23. Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018 Sep; 78:889-95. IF: 2.8
24. Petrioli R, Chirra M, Messuti L, Fiaschi AI, Savelli V, Martellucci I, Francini E. Efficacy and safety of regorafenib with schedule 2/1 for patients ≥75 years with metastatic colorectal cancer (mCRC) after failure of two lines of chemotherapy. Clin Colorectal Cancer. 2018 Dec; 17(4):307-312. IF: 3.4
25. Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ. Clinical outcomes of first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer after androgen deprivation therapy + docetaxel or adt alone for metastatic hormone-sensitive prostate cancer. Clin Genitourin Cancer. 2018 Apr; 16(2):130-134. IF: 3.2
26. Moreira RB, Debiasi M, Francini E, Nuzzo PV, De Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide a meta-analysis of randomized controlled trials. Oncotarget. 2017 Aug; 8:84572-84578. IF: 5.168
27. Francini E,Taplin ME. Prostate cancer: developing novel approaches to castration-sensitive disease. Cancer. 2017 Jan; 123(1):29-42.IF: 6.2
28. Francini E,Sweeney CJ.Docetaxel activity in the era of life-prolonging hormonal therapies for metastatic castration-resistant prostate cancer. Eur Urol. 2016Sep; 70(3):410-2. IF: 23.4
29. Petrioli R, Roviello G, Zanotti L, Roviello F, Polom K, Bottini A, Marano L, Francini E, Marrelli D, Generali D. Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016 Jun;102:82-8. IF: 6.2
30. Petrioli R, Francini E, Roviello G. Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol. 2015 Oct; 6(5):99-103. IF: 2.8
31. Roviello G, Francini E,Perrella A, Laera L, Mazzei MA, Guerrini S, Petrioli R. An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer. Cancer Biol Ther. 2015; 16(12):1720-5. IF: 3.6
32. Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, Marrelli D, Roviello F, Bianco V, Francini E. Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer. Future Oncol. 2015 Sep; 11(18):2563-74 IF: 3.3
33. Petrioli R, Francini E, Roviello F, Marrelli D, Miano ST, Fiaschi AI, Laera L, Bellini MA, Roviello G. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥75years with impaired performance status. J Geriatr Oncol. 2015 Sep; 6(5):380-6IF: 3.0
34. Francini E, Fiaschi AI, Petrioli R, Bianco V, Laera L, Francini F, Roviello G. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.Anticancer Drugs. 2015 Sep; 26(8):910-1. IF: 2.3
35. Petrioli R, Francini E, Laera L, Fiaschi AI, Ponchietti R, Roviello G. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.Cancer Chemother Pharmacol. 2015 Sep; 76(3):439-45. Epub 2015 Jun 17. IF: 3.0
36. Petrioli R, Roviello G, Laera L, Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Martellucci I, Bianco V, Francini E. Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: a single-institution experience.Clin Lung Cancer. 2015 Nov; 16(6):e229-34. IF: 3.6
37. Francini E, Fiaschi AI, Petrioli R, Laera L, Bianco V, Ponchietti R, Roviello G.Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.Anticancer Drugs. 2015 Sep; 26(8):884-7. IF: 2.3
38. Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, Bianco V, Francini E. Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study. Anticancer Drugs. 2015 Sep; 26(8):878-83. IF: 2.3
39. Roviello G, Petrioli R, Laera L, Francini E. The third line of treatment for metastatic prostate cancer patients: Option or strategy? Crit Rev Oncol Hematol. 2015 Sep; 95(3):265-71. IF: 6.2
40. Petrioli R, Francini E, Fiaschi AI, Laera L, Miano ST, DE Rubertis G, Roviello G.Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.Anticancer Res. 2015 May; 35(5):3097-102. IF: 2.435
41. Petrioli R, Francini E, Fiaschi AI, Laera L, Roviello G.Targeted Therapies for Prostate Cancer.Cancer Invest. 2015 Aug; 33(7):276-85. IF: 2.4
42. Petrioli R, Roviello G, Fiaschi AI, Laera L, Bianco V, Ponchietti R, Barbanti G, Francini E. Low-dose Estramustine Phosphate and concomitant low dose Acetylsalicyclic Acid in heavily pretreated patients with advanced castrate-resistant prostate cancer. Clin Genitourin Cancer. 2015 Oct; 13(5):441-6. IF: 3.2
43. Petrioli R, Roviello G, Fiaschi AI, Laera L, Roviello F, Marrelli D, Francini E. Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. Anticancer Drugs. 2015 Jul; 26(6):682-6. IF: 2.3
44. Petrioli R, Francini E, Fiaschi AI, Laera L, Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Bianco V, Roviello G.Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.Med Oncol. 2015 Apr; 32(4):587. IF: 3.4
45. Petrioli R, Francini E, Roviello F, Marrelli D, Fiaschi AI, Laera L, Rossi G, Bianco V, Brozzetti S, Roviello G. Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Cancer Chemother Pharmacol. 2015 May; 75(5):941-7. IF: 3.0
46. Roviello G, Francini E, Perrella A, Laera L, Mazzei MA, Guerrini S, Roviello F, Marrelli D, Petrioli R.Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. Cancer Biol Ther. 2015 Apr 3; 16(4):493-7. IF: 3.6
47. Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Barbanti G, Bianco V, Brozzetti S, Francini E. Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.Med Oncol. 2015 Mar; 32(3):485. IF: 3.4
48. Petrioli R, Roviello G, Fiaschi AI, Laera L, Marrelli D, Roviello F, Francini E.Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Cancer Chemother Pharmacol. 2015 Apr; 75(4):683-90. IF: 3.0
49. Francini E, Petrioli R, Fiaschi AI, Laera L, Roviello G. Effects of abiraterone acetate on chronic kidney disease in 2 patients wth metastatic castration-resistant prostate cancer. Medicine (Baltimore). 2014 Dec; 93(27):e163. IF: 1.817
50. Francini E, Mazzaroppi S, Fiaschi AI, Petrioli R, Laera L, Roviello G, Pira T, Pellicelli AM, Bianco V. Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma. J Am Geriatr Soc. 2014 Nov; 62(11):2204-5. IF: 6.3
51. Francini E, Petrioli R, Rossi G, Laera L, Roviello G.  PSA response rate as a surrogate rate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castrate-resistant prostate cancer: an analysis of 22 trials. Tumour Biol. 2014 Nov; 35(11):10601-7.
52. Francini E, Bianco V. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC). Hepatology. 2014 Aug; 60(2):764-5. IF: 13.5
53. Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide.Expert Rev Anticancer Ther. 2014 Oct; 14(10):1135-40. IF: 4.2
54. Francini E,Roviello G.How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.Tumour Biol. 2014 Aug; 35(8):7391-2.
55. Francini E,Fiaschi AI, Petrioli R, Francini F, Bianco V, Perrella A, Paganini G, Laera L, Roviello G. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer. Anticancer Drugs. 2014 Apr; 25(4):472-477. IF: 2.3
56. Rossi L, Tomao F, Russo GL, Papa A, Zoratto F, Marzano R, Basso E, Giordani E, Verrico M, Ricci F, Pasciuti G, Francini E, Tomao S.Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. Ther Clin Risk Manag. 2013 Nov; 9:457-462. IF: 2.8
57. Roviello G, Petrioli R, Francini E. Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer. Int J Biol Markers. 2013 Apr; 28(3):326-328. IF: 2.0
58. Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab; Multidisciplinary Oncology Group On Gastrointestinal Tumors. Cancer Invest. 2012 Jan; 30(1):65-71. IF: 2.4
59. Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, Roviello G, Martellucci I, Chiriacò G, Miano ST, Marzocca G, Manganelli A, Ponchietti R, Savelli V, Petrioli R. Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. Prostate Cancer. 2011 Aug 21. IF: 4.2
60. Francini F, Pascucci A, Francini E, Miano ST, Bargagli G, Ruggiero G, Petrioli R. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. J Am Dent Assoc. 2011 May; 142(5):506-13. IF: 3.9
61. Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G, Barbanti G, Ponchietti R, Francini G. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. Br J Cancer. 2011 Feb 15; 104(4):613-9. IF: 8.8
62. Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. Int J Clin Oncol. 2011 Jun; 16(3):264 9; IF: 3.3
63. Licchetta A, Correale P, Migali C, Remondo C, Francini E, Pascucci A, Magliocca A, Guarnieri A, Savelli V, Piccolomini A, Carli AF, Francini G. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. J Chemother. 2010 Jun; 22(3):201-4. IF: 1.8
64. Petrioli R, Bargagli G, Lazzi S, Pascucci A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI, Lorenzi B, Francini G. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.; the Multidisciplinary Oncology Group in Gastrointestinal Tumors. Anticancer Drugs. 2010 Mar; 21(3):313-9. IF: 2.3
65. Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev. 2008 Dec; 34(8):710-8. IF: 11.8
66. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P, Francini G. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 trial). Clin Cancer Res. 2008 Jul 1; 14(13):4192-9. IF: 11.5
67. Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli S, Tanzini G, Battistelli S, Lorenzi M, Roviello F, Francini G. Multidisciplinary Oncology Group on Gastrointestinal Tumors. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anticancer Drugs. 2008 Jan; 19(1):91-6. IF: 2.3
68. Petrioli R, Paolelli L, Francini E, Marsili S, Pascucci A, Sciandivasci A, de Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. Anticancer Drugs. 2007 Aug; 18(7):817-20. IF: 2.3
69. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 2007 Oct; 100(4):775-9. IF: 4.5
70. Francini G, Paolelli L, Francini E, Pascucci A, Manganelli A, Salvestrini F, Petrioli R. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. Eur J Surg Oncol. 2008 Feb; 34(2):216-21. IF: 3.8
71. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M, Francini G. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008 Jan; 61(1):105-11. IF: 3.0
72. Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology.  2007 Jan; 69(1):142-6. IF: 3.3
73. Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, Roviello F, Nettuno R, Intrivici C, Tanzini G, Lorenzi M, Francini G. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.Oncology. 2006 Dec 15; 70(5):345-50. IF: 3.5
74. Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer. 2006 Jul 17;95(2):153-8. IF: 8.8

Publications from 1 to 74:    Impact Factor = 361.985

                                                H-index (Scopus – October 30, 2023) = 21

                                                Citations (Scopus – October 30, 2023) = 1269

Abstracts/Posters, Book chapters, Editorials

• Francini E, Gray KP, Xie W, Kantoff PW, Valenca L, Bernard B, Albiges L, Shaw G, Harshman LC, Taplin ME, Sweeney CJ. Prior Therapy and Volume of Disease are Prognostic for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Hospital-based Database. Poster at 2017 Genitourinary Cancers Symposium – ASCO Meetings, Orlando (FL), USA.J Clin Oncol 35, 2017 (suppl 6S; abstr 221).
• Francini E, Gray KP, Evan C, Kaymakcalan MD, Shaw GK, Kantoff PW, Taplin ME, Sweeney CJ. Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry. Abstract at 2017 ASCO Annual Meeting, Chicago (IL), USA. J Clin Oncol 35, 2017 (suppl e16515).
• Kantoff PW, Spratt DE, Francini E. Androgen Blockade and Salvage Radiation Therapy in Prostate Cancer: Cautious Optimism Amid Unanswered Questions. Invited Editorial in ASCO Post. June 10, 2017.
• Francini E, Yip S, Ahmed NS, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ. Outcomes of Prechemotherapy (preCRx) Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after ADT + Docetaxel (D) or ADT Alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Multi-Institution Hospital-based Registry. Poster at ESMO 2017 Congress, Madrid (Spain). Ann Oncol 28, 2017 (suppl 5; abstr 806).
• Francini E, Gray KP, Shaw G, Evan C, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ. Impact of New Systemic Therapies on Overall Survival (OS) of Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) in a Hospital-based Registry. Poster at 2018 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 36, 2018 (suppl 6S; abstr 203).
• Zhang L, Gray KP, Shaw G, Evan C, Francini E, Sweeney CJ. Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases. Poster at 2018 ASCO Annual Meeting, Chicago (IL), USA. J Clin Oncol 36, 2018 (suppl; abstr 5049).
• Boccardo F, Francini E, Francini G, Zanardi E. Book chapter Neoplasie prostatiche. In: Manuale di oncologia medica. COMU Collegio degli Oncologi Medici Italiani, Aglietta M, editors. 2018; 246-64.
• Spini A, Roberto G, Ciccone V, Pascucci A, Rosellini P, Francini E, Donnini S, Gini R, Ziche M. Relevance of Gender In the Drug-utilization pattern of Non Small Cell Lung Cancer patients at University Hospital of Siena, Italy (UHS). Abstract at OSSD 2019, Washington (DC), USA.
• Frullanti E, Palmieri M, Baldassarri M, Fava F, Fabbiani A, Gelli E, Tita R, Torre P, Petrioli R, Hadijstilianou T, Galimberti D, Cinotti E, Mencarelli MA, Pinto AM, Francini E, Marsili S, Francini G, Renieri A. Specific clonal expansion at disease progression (PD) in solid cancers pinpointed by cell free DNA analysis. Abstract at 2019 ASCO Annual Meeting, Chicago (IL), USA. J Clin Oncol 37, 2019 (suppl; abstr e13144).
• Miano ST, Francini G, Petrioli R, Civitelli S, Francini E. Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT).Posterat 2019 ASCO Annual Meeting, Chicago (IL), USA.J Clin Oncol 37, 2019 (suppl; abstr 11052).
• Francini E, Montagnani F, Nuzzo P, Alimohamed NS, Moreno I, Rosellini P, Gonzalez-Velez M, Rubio-Perez J, Zhang L, Shaw GK, Crivelli F, Petrioli R, Bengala C, Francini G, Garcia-Foncillas J, Bryce AH, Sweeney CJ, Harshman LC, Lee-Ying R, Heng DYC. Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry. Abstract at 2019 ASCO Annual Meeting, Chicago (IL), USA. J Clin Oncol 37, 2019 (suppl; abstr e16508).
• Spini A, Roberto G, Bellan C, Rosellini P, Pascucci A, Donnini S, Caldarella A, Barchielli A, Furiesi F, Leoncini L, Francini E, Bartolini C, Giorgi S, Zappa M, Ziche M, Gini R. Using Linked Administrative And Pathology Database To Describe Treatment Patterns Of Non-small-cell Lung Cancer Patients At The Azienda Ospedaliera Universitaria Senese. Abstract at 35^th ICPE, 24-28th August 2019, Philadelphia (PA), USA.
• Correale P, Staropoli N, Pastina P, Giannicola R, Botta C, Francini E, Ridolfi L, Mini E, Ciliberto D, Agostino RM, Strangio A Azzarello D Nardone V, Falzea A, Tassone P, Giordano A, Pirtoli L, Francini, G, Tagliaferri, PS. GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis. Abstract at ESMO 2019 Congress, Barcelona (Spain). Annal Oncol 30, 2019 (suppl 5; abstr 1204P).
• Francini E, Ou FS, Rhoades J, Wolfe EG, O’Connor E, Ha G, Gydush G, Kelleher KM, Bhatt RP, Balk SP, Sweneey CJ, Adalsteinsson V, Taplin ME, Choudhury AD.Circulating free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). Poster at 2020 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 38, 2020 (suppl; abstr 174).
• Francini E, Montagnani F, Nuzzo P, Gonzalez-Velez M, Alimohamed NS, Cigliola A, Moreno I, Rubio-Perez J, Crivelli F, Shaw GK, Petrioli R, Bengala C, Francini G, Garcia-Foncillas J, Bryce AH, Sweeney CJ, Higano CS, Harshman LC, Lee-Ying R, Heng DYC. Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) vs. AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database. Poster at 2020 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 38, 2020 (suppl; abstr 30).
• Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts SR, Hubbard JM, Yoon HH, Francini G. CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ). Poster at 2020 Gastrointestinal Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 38, 2020 (suppl; abstr 167).
• Boccardo F, Bianco R, Francini E, Zanardi E. Book chapter Neoplasie prostatiche. In: Manuale di oncologia medica. II edizione. COMU Collegio degli Oncologi Medici Italiani, Aglietta M, editors. Torino: Edizioni Minerva Medica; 2021; 273-89.
• Yang DD, Francini E, Jett Crowdis J, Bin Riaz I, Rickles-Young M; Tsuji J, Cibulskis C, Whelpley B, Reardon B, Park J, Huang FW, Van Allen EM, Choudhury AD. Genomic analysis of circulating tumor DNA identifies recurrent molecular features with clinical significance in advanced prostate cancer. Abstract at American Society for Radiation Oncology (ASTRO) 64^th Annual Meeting, 23-26 October 2022.
• Lee-Ying R, Saieva C, Nuzzo PV, Malgeri A, Fotia G, Zanardi E, Rossetti S, Valença L, Patrikidou A, Modesti M, Martins Oliveira T, Pignata S, Fornarini G, Procopio G, Santini D, Sweeney CJ, Heng DY, De Giorgi U, Russo A, Francini E. Clinical outcomes of Abiraterone Acetate (AA) or Enzalutamide (E) as 1st line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: a SPARTACUSS – Meet-URO 26 study. Poster at 2023 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol41, no. 6_suppl (February 20, 2023) 107-107.
• Gennusa V, Saieva C, Lee-Ying R, Nuzzo PV, Spinelli G, Zanardi E, Fotia G, Rossetti G, Valença L, Patrikidou A, Andrade L, Pereira Mestre R, Fornarini G, Procopio G, Santini D, Sweeney CJ, Heng DY, De Giorgi U, Russo A, Francini E. Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as 2nd line therapy (Rx) after progression on alternative ARSi as 1st line Rx for the elderly ≥75 years old with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: a SPARTACUSS – Meet-URO 26 study. Poster at 2023 Genitourinary Cancers Symposium – ASCO Meetings, San Francisco (CA), USA. J Clin Oncol 41, no. 6_suppl (February 20, 2023) 166-166.

INVITED PRESENTATIONS, PANELS/CHAIRMANSHIPS, SEMINARIES

• Francini E. Salvage Hormonal Therapy in Prostate Cancer. Invited oral presentation at L'integrazione Terapeutica con i Farmaci Target in Oncologia annual meeting. Rome, Italy. October 4-5, 2013.
• Francini E. Emesis, Anemia, Neutropenia. Invited oral presentation at Focus sul Carcinoma della Mammella nella Paziente Anziana. Rome, Italy. November 28, 2013.
• Francini E. Pain Management in the Elderly Patient with Metastatic Disease. Invited oral presentation at Focus sul Carcinoma della Mammella nella Paziente Anziana. Rome, Italy. October 8, 2014.
• Francini E. Brain Tumors, Medical Therapy and Integrated Protocols. Invited oral presentation at Diagnosi e Trattamento delle Neoplasie in Età Geriatrica. Rome, Italy. February 20, 2015.
• Francini E. New developments in the management of CINV. Invited oral presentation in collaboration with Italfarmaco S.p.A. Sienna, Italy. May 13, 2015.
• Francini E. Management of Emesis and Neutropenia. Invited oral presentation at Focus sul Carcinoma della Mammella nella Paziente Anziana. Rome, Italy. October 30, 2015.
• Francini E. Evoluzione delle Linee di Trattamento del Cancro Prostatico Metastatico: Note per l’Urologo Territoriale. Invited oral presentation at V Congresso Nazionale AIMUT. Pisa, Italy. September 15-16, 2017.
• Francini E. Nuovi Orizzonti nel Trattamento del Carcinoma Prostatico Castration Naive. Invited oral presentation at Approccio Multidisciplinare al Paziente con Carcinoma della Prostata: Specialisti a Confronto. Rieti, Italy. September 29, 2017.
• Francini E. Carcinoma della Prostata: Quali Prospettive per l’Immunoterapia? Invited oral presentation at Immuno-Oncologia: Le Nuove Possibilità Terapeutiche. Bari, Italy. November 27, 2017.
• Francini E. Trattamento del mHSPC ed Implicazioni Terapeutiche Successive. Invited oral presentation at Il Paziente Oncologico Anziano Gestione e Trattamento. Sienna, Italy. November 23, 2018.
• Francini E. Role of Chemotherapy in Prostate Cancer. Invited oral presentation at “First International congress of Bioimmunotherapy of cancer An International multidisciplinary meeting” – Reggio Calabria, Italy. April 12-14, 2019.
• Francini E. Il Ruolo della Chemioterapia nel Carcinoma della Prostata. Seminary at the School of Medical Oncology, Università degli Studi di Firenze – Florence, Italy. July 24, 2019.
• Francini E. Il Paziente Oligometastatico: Il Ruolo dell’Ormonoterapia. Invited oral presentation at “Prostate Cancer Match Point” – Naples, Italy. October 11-12, 2019.
• Francini E. Terapia medica nei tumori della prostata castrazione-resistenti M0. Invited oral presentation at Congresso Regionale AURO.it Toscana – Grosseto, Italy. November 30, 2019.
• Francini E. Definizione e trattamento del carcinoma della prostata resistente alla castrazione non metastatico (nmCRPC).Seminary at the School of Medical Oncology, Università degli Studi di Firenze – Florence, Italy. May 21, 2019.
• Francini E. Carcinoma della prostata sensibile alla castrazione metastatico (mCSPC): attuale stato dell’arte. Seminary at the School of Medical Oncology, Università degli Studi di Firenze – Florence, Italy. September 3, 2021.
• Francini E. Carcinoma della prostata sensibile alla castrazione metastatico (mCSPC): stato dell’arte ed aggiornamenti Seminary at the School of Medical Oncology, Università degli Studi di Firenze – Florence, Italy. July 29, 2022.
• Francini E. Il ruolo dei PARP-inibitori nel trattamento della malattia prostatica. Invited oral presentation at “Novità Nel Trattamento Integrato Dei Tumori Del Tratto Genito-Urinario” – Florence, Italy. October 27, 2022.
• Francini E. La terapia ormonale nella sequenza terapeutica: apalutamide, abiraterone acetato, darolutamide e enzalutamide. Invited oral presentation at “Approccio multidisciplinare al paziente anziano con carcinoma della prostata: specialisti a confronto”. Rome, Italy. 2 December, 2022.
• Francini E. Treatment of metastatic castration-sensitive prostate cancer (mCSPC): the clinical outliers. Seminary at HM Sanchinarro University Hospital. Madrid, Spain. January 25, 2023.
• Francini E. Panel Discussant at “EAU UROonco23”. Gothenburg, Sweden, June 30 – July, 2023.
• Francini E. Carcinoma della prostata sensibile alla castrazione metastatico (mCSPC): stato dell’arte e strategie di trattamento. Seminary at the School of Medical Oncology, Università degli Studi di Firenze – Florence, Italy. October 13, 2023.
• Francini E. Chairman at “Novità nel trattamento integrato dei tumori del tratto genito-urinario”. Florence, October 26, 2023.
• Francini E. Role of the PARP inhibitors in the treatment of mCRPC. Seminary at the School of Medical Oncology, Università degli Studi di Firenze – Florence, Italy. November 10, 2023.

PERSONAL SKILLS AND COMPETENCES

• Public speaking
• Spoken languages:

-        Italian (mother tongue)

-        English (excellent)         

-        Spanish (excellent)        

-        Portuguese (excellent)  

References available upon request.

October 30, 2023

• Translational precision oncology for prostate cancer
• Tumor microenvironment factors for prognostic and predictive use
• Clinical outliers predictive of resistance to treatment
• Cell-free DNA as biomarker of resistance to therapy